American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 984-989 , May 2002

Effect of raloxifene on the ovarian circulation in women after menopause

Received 22 May 2001 ,Revised 5 September 2001 ,Accepted 20 December 2001.

References 

  1. Grodstein F, Stampfer MJ, Manson JE, et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461
  2. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Estrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis. 1995;6:417–422
  3. Bush TL, Barrott-Conor E, Cowan LD, et al.  Cardiovascular mortality and noncontraceptive estrogen use in women: results from the lipid research clinic's program follow-up study. Circulation. 1987;75:1002–1012
  4. Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health. 1990;80:1266–1268
  5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–313
  6. Colditz GA, Hankinson SE, Hunter DJ, et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–1593
  7. Fuchs-Young R, Glasebrook AL, Short LL, et al.  Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355–360
  8. Black LJ, Sato M, Rowley ER, et al.  Raloxifene (LY 139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63–69
  9. Turner CH, Sato M, Bryant HV. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135:2001–2005
  10. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835–842
  11. Draper MW, Boss SM, Huster WJ, Neild JA. Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism-dose response relationships [abstract]. Calcif Tissue Int. 1994;54:339
  12. Delmas PD, Bjarnason NH, Mitlak BH, et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647
  13. Kauffman RF, Bensch WR, Roudebush RE, et al.  Hypocholesterolemic activity of raloxifene (LY 139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther. 1997;280:146–153
  14. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458–1464
  15. Anzano MA, Peer CW, Smith JM, et al.  Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88:123–125
  16. Sato M, Glasebrook AL, Bryant HV. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab. 1995;12(Suppl):S9–S20
  17. SAS/STAT software . Changes and enhancement through release 6.11. In: Cary (NC): SAS Institute Inc; 1996;p. 617–626
  18. Jenrich RI, Schluchter MD. Unbalanced repeated measure models with structured covariance matrices. Biometrics. 1986;42:805–820
  19. Kurjak A, Kupesic S. Ovarian senescence and its significance on uterine and ovarian perfusion. Fertil Steril. 1995;64:532–537
  20. Penotti M, Sironi L, Miglierina L, et al.  The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: a randomized controlled study. Am J Obstet Gynecol. 1998;178:801–805
  21. Exacoustos C, Lello S, Caporale E, et al.  Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow Doppler: study in different phases of sequential therapy. Fertil Steril. 1999;71:536–543
  22. Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S. Oestrogens, arterial status and postmenopausal women. Lancet. 1990;335:1470–1471
  23. Stampfer MJ, Colditz GA, Willet WC, et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurse's health study. Obstet Gynecol. 1998;72:235–305
  24. Figtree GA, Lu Y-q, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 1999;100:1095–1101
  25. Palmer RMJ, Rees DD, Ashton DS, Noncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251–1256
  26. Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res. 1989;65:1798–1803
  27. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular response to raloxifene in the sheep. Am J Obstet Gynecol. 2000;182:521–528
  28. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric acid synthase. J Clin Endocrinol Metab. 2000;85:2966–2969
  29. Wellman GC, Bonev AD, Nelson MT, Brayden JE. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca+2 dependent K+channels. Circ Res. 1996;79:1024–1030
  30. Hillard TC, Bourne TH, Whitehead MI, Corayford TB, Collins WP, Campbell SG. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril. 1991;58:959–963

☆ Reprint requests: Arie L. Lidor, MD, Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer 52621, Israel. E-mail: lidor_md@netvision.net.il

PII: S0002-9378(02)20192-1

doi: 10.1067/mob.2002.122401

American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 984-989 , May 2002

Article Tools

* Image Usage & Resolution